Gain Therapeutics, Inc.
GANX · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.05 | -0.12 | -0.26 | -0.01 |
| FCF Yield | -38.23% | -44.38% | -39.82% | -22.57% |
| EV / EBITDA | -2.01 | -1.43 | -1.76 | -1.44 |
| Quality | ||||
| ROIC | -246.36% | -159.43% | -87.99% | -37.63% |
| Gross Margin | 0.00% | -45.67% | 54.20% | -4,242.11% |
| Cash Conversion Ratio | 0.92 | 0.85 | 0.84 | 0.89 |
| Growth | ||||
| Revenue 3-Year CAGR | -100.00% | -25.59% | 66.22% | 48.01% |
| Free Cash Flow Growth | -0.08% | -27.48% | -18.87% | -282.08% |
| Safety | ||||
| Net Debt / EBITDA | 0.49 | 0.49 | 0.34 | 2.55 |
| Interest Coverage | 0.00 | 0.00 | 0.00 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | -4,108.25 | -4,384.60 | -8,978.96 | 403.82 |